Esperion Therapeutics Operating Margin vs. Current Valuation
| ESPR Stock | USD 3.48 0.04 1.14% |
Esperion Therapeutics Operating Profit Margin |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.89 | 0.91 |
|
|
For Esperion Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Esperion Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Esperion Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Esperion Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Esperion Therapeutics over time as well as its relative position and ranking within its peers.
Esperion Therapeutics' Revenue Breakdown by Earning Segment
Check out Investing Opportunities.
Esperion Therapeutics Revenue Breakdown by Earning Segment
By analyzing Esperion Therapeutics' earnings estimates, investors can diagnose different trends across Esperion Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes.
Can Biotechnology industry sustain growth momentum? Does Esperion have expansion opportunities? Factors like these will boost the valuation of Esperion Therapeutics. Projected growth potential of Esperion fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Esperion Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.54) | Revenue Per Share | Quarterly Revenue Growth 0.691 | Return On Assets | Return On Equity |
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Esperion Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Esperion Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Esperion Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Esperion Therapeutics Current Valuation vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Esperion Therapeutics's current stock value. Our valuation model uses many indicators to compare Esperion Therapeutics value to that of its competitors to determine the firm's financial worth. Esperion Therapeutics is rated # 4 in operating margin category among its peers. It is rated # 3 in current valuation category among its peers . At this time, Esperion Therapeutics' Operating Profit Margin is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Esperion Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Esperion Current Valuation vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Esperion Therapeutics |
| = | (0.11) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Esperion Therapeutics |
| = | 1.03 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Esperion Current Valuation vs Competition
Esperion Therapeutics is rated # 3 in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 8.01 Billion. Esperion Therapeutics retains roughly 1.03 Billion in current valuation claiming about 13% of equities under Health Care industry.
Esperion Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Esperion Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Esperion Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Esperion Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Esperion Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | 49 M | 51.4 M | |
| Net Loss | -46.6 M | -48.9 M | |
| Income Tax Expense | -59.5 M | -56.5 M | |
| Income Before Tax | -46.6 M | -48.9 M | |
| Total Other Income Expense Net | -95.5 M | -90.8 M | |
| Net Loss | -46.6 M | -48.9 M | |
| Non Operating Income Net Other | 3 M | 2.3 M | |
| Net Loss | -210.3 M | -220.8 M | |
| Net Interest Income | -53.3 M | -50.7 M | |
| Interest Income | 4 M | 3.5 M | |
| Change To Netincome | 17.5 M | 18.7 M | |
| Net Loss | (0.25) | (0.26) | |
| Income Quality | 0.53 | 0.84 | |
| Net Income Per E B T | 0.79 | 0.70 |
Esperion Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Esperion Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Esperion Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Esperion Therapeutics' important profitability drivers and their relationship over time.
Esperion Therapeutics Earnings Estimation Breakdown
The calculation of Esperion Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Esperion Therapeutics is estimated to be 0.024175 with the future projection ranging from a low of -0.08 to a high of 0.145. Please be aware that this consensus of annual earnings estimates for Esperion Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.08 Lowest | Expected EPS | 0.14 Highest |
Esperion Therapeutics Earnings Projection Consensus
Suppose the current estimates of Esperion Therapeutics' value are higher than the current market price of the Esperion Therapeutics stock. In this case, investors may conclude that Esperion Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Esperion Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 8 | 57.16% | 0.0 | 0.024175 | -0.54 |
Esperion Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Esperion Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Esperion Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Esperion Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Esperion Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Esperion Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Esperion Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Esperion Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Esperion Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | 0.02 | -0.16 | -0.18 | 900 | ||
2025-08-13 | 2025-06-30 | -0.14 | -0.06 | 0.08 | 57 | ||
2025-05-05 | 2025-03-31 | -0.15 | -0.2063 | -0.0563 | 37 | ||
2025-02-25 | 2024-12-31 | -0.1575 | -0.1013 | 0.0562 | 35 | ||
2024-11-05 | 2024-09-30 | -0.18 | -0.15 | 0.03 | 16 | ||
2024-08-12 | 2024-06-30 | -0.18 | -0.33 | -0.15 | 83 | ||
2024-05-07 | 2024-03-31 | 0.05 | 0.34 | 0.29 | 580 | ||
2024-02-27 | 2023-12-31 | -0.48 | -0.5 | -0.02 | 4 | ||
2023-11-07 | 2023-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2023-08-01 | 2023-06-30 | -0.61 | -0.46 | 0.15 | 24 | ||
2023-05-09 | 2023-03-31 | -0.65 | -0.79 | -0.14 | 21 | ||
2023-02-21 | 2022-12-31 | -0.84 | -0.76 | 0.08 | 9 | ||
2022-11-01 | 2022-09-30 | -0.92 | -0.81 | 0.11 | 11 | ||
2022-08-02 | 2022-06-30 | -0.93 | -1.05 | -0.12 | 12 | ||
2022-05-03 | 2022-03-31 | -1.04 | -0.93 | 0.11 | 10 | ||
2022-02-22 | 2021-12-31 | -2.27 | -1.77 | 0.5 | 22 | ||
2021-11-02 | 2021-09-30 | -2.8 | -2.62 | 0.18 | 6 | ||
2021-08-03 | 2021-06-30 | -1.84 | -1.67 | 0.17 | 9 | ||
2021-05-04 | 2021-03-31 | -2.52 | -3.5 | -0.98 | 38 | ||
2021-02-23 | 2020-12-31 | -3.76 | -3.89 | -0.13 | 3 | ||
2020-11-02 | 2020-09-30 | -3.44 | -3.07 | 0.37 | 10 | ||
2020-08-10 | 2020-06-30 | 1.71 | 4.32 | 2.61 | 152 | ||
2020-05-06 | 2020-03-31 | -3.3 | -2.84 | 0.46 | 13 | ||
2020-02-27 | 2019-12-31 | -2.67 | -2.26 | 0.41 | 15 | ||
2019-11-06 | 2019-09-30 | -1.95 | -2.52 | -0.57 | 29 | ||
2019-08-08 | 2019-06-30 | -1.86 | -2.01 | -0.15 | 8 | ||
2019-05-08 | 2019-03-31 | 0.74 | 3.07 | 2.33 | 314 | ||
2019-02-28 | 2018-12-31 | -1.42 | -2.24 | -0.82 | 57 | ||
2018-11-01 | 2018-09-30 | -1.63 | -1.86 | -0.23 | 14 | ||
2018-08-02 | 2018-06-30 | -1.72 | -1.71 | 0.01 | 0 | ||
2018-05-02 | 2018-03-31 | -1.56 | -1.73 | -0.17 | 10 | ||
2018-02-20 | 2017-12-31 | -1.79 | -1.44 | 0.35 | 19 | ||
2017-11-07 | 2017-09-30 | -1.78 | -1.86 | -0.08 | 4 | ||
2017-08-08 | 2017-06-30 | -1.61 | -1.92 | -0.31 | 19 | ||
2017-05-04 | 2017-03-31 | -1.42 | -1.8 | -0.38 | 26 | ||
2017-02-22 | 2016-12-31 | -1.22 | -1.29 | -0.07 | 5 | ||
2016-11-03 | 2016-09-30 | -0.82 | -0.77 | 0.05 | 6 | ||
2016-08-04 | 2016-06-30 | -0.78 | -0.62 | 0.16 | 20 | ||
2016-05-04 | 2016-03-31 | -0.74 | -0.65 | 0.09 | 12 | ||
2016-02-25 | 2015-12-31 | -0.63 | -0.58 | 0.05 | 7 | ||
2015-11-05 | 2015-09-30 | -0.6 | -0.57 | 0.03 | 5 | ||
2015-08-06 | 2015-06-30 | -0.58 | -0.55 | 0.03 | 5 | ||
2015-05-07 | 2015-03-31 | -0.48 | -0.56 | -0.08 | 16 | ||
2015-03-05 | 2014-12-31 | -0.55 | -0.49 | 0.06 | 10 | ||
2014-11-10 | 2014-09-30 | -0.68 | -0.64 | 0.04 | 5 | ||
2014-08-12 | 2014-06-30 | -0.6 | -0.6 | 0.0 | 0 | ||
2014-05-12 | 2014-03-31 | -0.62 | -0.51 | 0.11 | 17 | ||
2014-03-05 | 2013-12-31 | -0.5 | -0.63 | -0.13 | 26 | ||
2013-11-06 | 2013-09-30 | -0.4 | -0.34 | 0.06 | 15 |
Use Esperion Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Esperion Therapeutics Pair Trading
Esperion Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Esperion Therapeutics position
In addition to having Esperion Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Growth Funds Thematic Idea Now
Small Growth Funds
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.